Publications

  1. L. V. Myznikov, J. Roh, T. V. Artamonova, A. Hrabálek, G. I. Koldobskii, Synthesis of 5-Substituted Tetrazoles under Microwave Activation. Russ. J. Org. Chem. 2007, 43 (5), 765-768. (IF2007 = 0.511)
  2. J. Roh,* T. V. Artamonova, K. Vávrová, G. I. Koldobskii, A. Hrabálek, Practical Synthesis of 5-Substituted Tetrazoles under Microwave Irradiation. Synthesis 2009, (13), 2175-2178. (IF2009 = 2.572)

  3. J. Roh,* K. Vávrová, A. Hrabálek. One-pot regioselective vinylation of tetrazoles: preparation of 5-substituted 2-vinyl-2H-tetrazoles. Tetrahedron Lett. 2010, 51 (10), 1411–1414. (IF2010 = 2.618)

  4. K. Vávrová, P. Kovaříková, B. Školová, M. Líbalová, J. Roh, R. Čáp, A. Holý, A. Hrabálek, Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr‑PMEDAP. Pharm. Res. 2011; 28 (12), 3105-3115. (IF2011 = 4.093) (Q1)

  5. V. Novakova, J. Roh, P. Gela, J. Kuneš, P. Zimcik, Azaphthalocyanines with fused triazolo rings: formation of sterically stressed constitutional isomers. Chem. Commun. 2012, 48, 4326-4328. (IF2012 = 6.378) (Q1)

  6. J. Roh,* K. Vavrova, A. Hrabalek, Synthesis and Functionalization of 5-Substituted Tetrazoles, Eur. J. Org. Chem., 2012, 6101–6118. (IF2012 = 3.344) (Q1)

  7. B. Janůšová, B. Školová, K. Tükörová, L. Wojnarová, T. Šimůnek, P. Mladěnka, T. Filipský, M. Říha, J. Roh, K. Palát, A. Hrabálek, K. Vávrová, Amino acid derivatives as transdermal permeation enhancers. J. Control. Release 2013, 165 (2), 91-100. (IF2013 = 7.261) (Q1)

  8. L. Myznikov, U. Dmitrieva, T. Artamonova, J. Roh, A. Hrabálek, Y. Zevatskii, An Efficient Synthesis of 1-Substituted 5-Bromo-1H-tetrazoles. Synthesis 2013, 45, 2029-2033. (IF2013 =2.443)

  9. G. Karabanovich, J. Roh,* Z. Padělková, Z. Novák, K. Vávrová, A. Hrabálek, One-pot synthesis of 1-substituted-5-alkylselanyl-1H-tetrazoles from isoselenocyanates: Unexpected formation of N-alkyl-N-arylcyanamides and (Z)-Se-alkyl-N-cyano-N,N’-diarylisoselenoureas. Tetrahedron 2013, 69, 8798-8808. (IF2013 = 2.817)

  10. B. Školová, B. Janůšová, J. Zbytovská, G. Gooris, J. A. Bouwstra, P. Slepička, P. Berka, J. Roh, K. Palát, A. Hrabálek, K. Vávrová. Ceramides in the Skin Lipid Membranes: Length Matters. Langmuir 2013, 29, 15624-15633. (IF2013 = 4.384) (Q1)

  11. D. Diblikova, M. Kopecna, B. Skolova, M. Krecmerova, J. Roh, A. Hrabalek, K. Vavrova. Transdermal Delivery and Cutaneous Targeting of Antivirals using a Penetration Enhancer and Lysolipid Prodrugs. Pharm. Res. 2014, 31 (4), 1071-1081. (IF2014 = 3.420) (Q1)

  12. J. Stariat, V. Suprunova, J. Roh, V. Sestak, T. Eisner, T. Filipsky, P. Mladenka, M. Nobilis, T. Simunek, J. Klimes, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: Application to a pilot pharmacokinetic study in rats. Biomed. Chromatogr. 2014, 28 (5), 621-629. (IF2014 = 1.723)

  13. B. Skolova, K. Jandovska, P. Pullmannova, O. Tesar, J. Roh, A. Hrabalek, K. Vavrova. The Role of the Trans Double Bond in Skin Barrier Sphingolipids: Permeability and Infrared Spectroscopic Study of Model Ceramide and Dihydroceramide Membranes. Langmuir 2014, 30 (19), 5527-5535. (IF2014 = 4.457) (Q1)

  14. A. Kovacik, J. Roh, K. Vavrova. The Chemistry and Biology of 6-Hydroxyceramide, the Youngest Member of the Human Sphingolipid Family. ChemBioChem 2014, 15 (11), 1555-1562. (IF2014 = 3.088)

  15. G. Karabanovich, J. Roh,* T. Smutný, J. Něměcek, P. Vicherek, J. Stolaříková, M. Vejsová, I. Dufková, K. Vávrová, P. Pávek, V. Klimešová, A. Hrabálek. 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. Eur. J. Med. Chem. 2014, 82, 324-340. (IF2014 = 3.447) (Q1)

  16. B. Skolova, K. Hudska, P. Pullmannova, A. Kovacik, K. Palat, J. Roh, J. Fleddermann, I. Estrela-Lopis, K. Vavrova. Different Phase Behavior and Packing of Ceramides with Long (C16) and Very Long (C24) Acyls in Model Membranes: Infrared Spectroscopy Using Deuterated Lipids. J. Phys. Chem. B 2014, 118 (35), 10460-10470. (IF2014 = 3.302)

  17. G. Karabanovich, J. Roh,* O. Soukup, I. Pávková, M. Pasdiorová, V. Tambor, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek. Tetrazole Regioisomers in the Development of Nitro Group-Containing Antitubercular Agents. Med. Chem. Commun. 2015, 6, 174-181. (IF2015 = 2.319)

  18. L. Lochman, J. Svec, J. Roh, V. Novakova. The role of the size of aza-crown recognition moiety in azaphthalocyanine fluorescence sensors for alkali and alkaline earth metal cations. Dyes Pigment. 2015, 121, 178-187. (IF2015 = 4.055) (Q1)

  19. A. Jirkovska, J. Roh, O. Lenčová-Popelová, E. Jirkovsky, K. Hruskova, E. Potuckova, H. Jansova, P. Haskova, P. Martinkova, T. Eisner, M. Kratochvil, J. Sus, M. Machacek, L. Tichotova, V. Gersl, D. S. Kalinowski, M. Muller, D. Richardson, K. Vavrova, M. Sterba, T. Simunek. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicol. Res. 2015, 4, 1098–1114. (IF2015 = 2.161)

  20. E. Potůčková, J. Roh, M. Macháček, S. Sahni, J. Stariat, V. Šesták, H. Jansová, P. Hašková, A. Jirkovská, K. Vávrová, P. Kovaříková, D. S. Kalinowski, D. R. Richardson, T. Šimůnek. In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS ONE 2015, 10 (10). e0139929. (IF2015 = 3.057) (Q1)

  21. L. Opálka, A. Kováčik, M. Sochorová, J. Roh, J. Kuneš, J. Lenčo, K. Vávrová. Scalable Synthesis of Human Ultralong Chain Ceramides. Org. Lett., 2015, 17 (21), 5456–5459. (IF2015 = 6.732) (Q1)

  22. V. Sestak, J. Stariat, J. Cermanova, E. Potuckova, J. Chladek, J. Roh, J. Bures, H. Jansova, P. Prusa, M. Sterba, S. Micuda, T. Simunek, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 2016, 6 (40), 42411-42428. (IF2016 = 5.168) (Q1)

  23. L. Lochman, J. Svec, J. Roh, K. Kirakci, K. Lang, P. Zimcik, V. Novakova. Metal-Cation Recognition in Water by a Tetrapyrazinoporphyrazine-Based Tweezer Receptor. Chem. Eur. J., 2016, 22(7), 2417-2426. (IF2016 = 5.317) (Q1)

  24. G. Karabanovich, J. Zemanová, T. Smutný, R. Székely, M. Šarkan, I. Centárová, A. Vocat, I. Pávková, P. Čonka, J. Němeček, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek, P. Pávek, S. T. Cole, K. Mikušová, J. Roh.* Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-Oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2016, 59, 2362−2380. (IF2016 = 6.259) (Q1)

  25. V. Sestak , J. Roh, L. Klepalova, P. Kovarikova. A UHPLC-UV-QTOF Study on the Stability of Carfilzomib, A Novel Proteasome Inhibitor. Journal of Pharmaceutical and Biomedical Analysis, 2016, 124, 365–373. (IF2016 = 3.255) (Q1)

  26. H. Jansová, J. Bureš, M. Macháček, P. Hašková, A. Jirkovská, J. Roh, Q. Wang, K. J. Franz, P. Kovaříková, T. Šimůnek. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350, 15–24. (IF2016 = 3.582) (Q1)

  27. A. Kováčik, L. Opálka, M. Šilarová, J. Roh, K. Vávrová. Synthesis of 6-hydroxyceramide using rutheniumcatalyzed hydrosilylation–protodesilylation. Unexpected formation of a long periodicity lamellar phase in skin lipid membranes. RSC Advances, 2016, 6, 73343–73350. (IF2016 = 3.108)

  28. J. Roh,* G. Karabanovich, V. Novakova, T. Šimůnek, K. Vávrová. Large-scale synthesis of piperazine-2,6-dione and its use in the synthesis of dexrazoxane analogues. Synthesis. 2016, 48, 4580-4588. (IF2016 = 2.650)

  29. G. Karabanovich, J. Němeček, L. Valášková, A. Carazo, K. Konečná, J. Stolaříková, A. Hrabálek, O. Pavliš, P. Pávek, K. Vávrová, J. Roh,* V. Klimešová. S-Substituted 3,5-Dinitrophenyl 1,3,4-Oxadiazole-2-thiols and Tetrazole-5-thiols as Highly Efficient Antitubercular Agents. Eur. J. Med. Chem. 2017, 126, 369-383. (IF2017 = 4.816) (Q1)

  30. J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh,* V. Klimešová. Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents. Eur. J. Med. Chem. 2017, 130, 419–432. (IF2017 = 4.816) (Q1)

  31. E. Mezeiova, J. Korabecny, V. Sepsova, M. Hrabinova, P. Jost, L. Muckova, T. Kucera, R. Dolezal, J. Misik, K. Spilovska, N. L. Pham, L. Pokrievkova, J. Roh, D. Jun, O. Soukup, D. Kaping, K. Kuca. Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy. Molecules 2017, 22, 1265. (IF2017 = 3.098)

  32. J. Roh *, G. Karabanovich, H. Vlčková, A. Carazo, J. Němeček, P. Sychra, L. Valášková, O. Pavliš, J. Stolaříková, V. Klimešová, K. Vávrová, P. Pávek, A. Hrabálek. Development of Water-Soluble 3,5-Dinitrophenyl Tetrazole and Oxadiazole Antitubercular Agents. Bioorg. Med. Chem. 2017, 25, 5468–5476. (IF2017 = 2.881)

  33. I. Melnikova, J. Roh, J. Kuneš, T. Artamonova, Y. Zevatskii, L. Myznikov. Non-catalyzed addition of heterocyclic thiols and 5-substituted-1H-tetrazoles to vinyl ethers. Tetrahedron Lett. 2017, 58, 3842–3845. (IF2017 = 2.125)

  34. J. Bureš, A. Jirkovská, V. Šesták, H. Jansová, G. Karabanovich, J. Roh, M. Štěrba, T. Šimůnek, P. Kovaříková. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology 2017, 392, 1-10. (IF2017 = 3.265)

  35. E. Jirkovský, A. Jirkovská, J. Bureš, J. Chládek, O. Lenčová, J. Stariat, Z. Pokorná, G. Karabanovich, J. Roh, P. Brázdová, T. Šimůnek, P. Kovaříková, M. Štěrba. Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart. 2018, (IF2018 = 3.615) (Q1)

  36. , , , , , and 2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress. Chem. Res. Toxicol., 2018, 31 (11), 1151–1163. (IF2018 = 3.274)

  37. P. Reimerova, A. Jirkovska, H. Piskackova, G. Karabanovich, J. Roh, T. Simunek, P. Sterbova-Kovarikova. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.  Sci. Rep. 2019, 9, Art. No. 4524. (IF2017 = 4.011) (Q1)

  38. P. Reimerova; J. Stariat, H. Piskackova, H. Jansova, J. Roh, D.S. Kalinowski, M. Machacek, T. Simunek, D. R. Richardson, P. Sterbova-Kovarikova. Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. Anal. Bioanal. Chem. 2019, 411(11), 2383-2394. (IF2017 = 3.286) (Q1)

  39. G. Karabanovich, J. Dušek, K. Savková, O. Pavliš, I. Pávková, J. Korabecny, T. Kučera, H. Kočová Vlčková, S. Huszár, Z. Konyariková, K. Konečná, O. Jandourek, J. Stolaříková, J. Korduláková, K. Vávrová, P. Pavek, V. Klimešová, A. Hrabalek, K. Mikušová, J. Roh*. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2′-Oxidase. J. Med. Chem. 2019,62, 8115-8139. (IF2018 = 6.054) (Q1)

  40. M. Kopecna, M. Machacek, A. Novackova, G. Paraskevopoulos, J. Roh, K. Vavrova. Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers. Sci. Rep. 2019, 9, 14617. (IF2018 = 4.011) (Q1)

© Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
Website information | Powered by Kentico